Amneal Pharmaceuticals (AMRX) Superinvestor holders
11 of the superinvestors we track hold Amneal Pharmaceuticals (AMRX) in their latest 13F filings, $109M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $39M, 2.4% of the portfolio.
In their latest quarter: 1 opened a new position, 1 added, 9 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Trimmed | 2,268,751 | $39M | 2.4% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 1,296,266 | $26M | 0.0% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 795,028 | $14M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 774,055 | $13M | 0.0% | Q2 2026 |
| Arrowstreet Capital | Trimmed | 334,758 | $6M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 233,270 | $4M | 0.0% | Q2 2026 |
| Jennison Associates | Added | 168,863 | $3M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 87,487 | $2M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Trimmed | 85,545 | $1M | 0.0% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Trimmed | 27,400 | $552,000 | 0.0% | Q3 2026 |
| Ken Tropin Graham Capital Management |
New position | 24,035 | $416,046 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 17 |
| Q4 2025 | 17 |
| Q3 2025 | 14 |
| Q2 2025 | 13 |
| Q1 2025 | 17 |
| Q4 2024 | 11 |
| Q3 2024 | 9 |
Questions about Amneal Pharmaceuticals
Which superinvestors own Amneal Pharmaceuticals?
11 of the superinvestors we track hold Amneal Pharmaceuticals (AMRX) in their latest 13F filings, $109M in total. Wilmot Harkey, Acadian, Cliff Asness, David Shaw, Arrowstreet Capital, Two Sigma.
Who is the largest superinvestor holder of AMRX?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $39M, 2.4% of the portfolio.
From Amneal Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.